Chongqing Lummy Pharmaceutical Co.Ltd(300006) ( Chongqing Lummy Pharmaceutical Co.Ltd(300006) ) announced on March 25 that the company achieved an operating revenue of 1.225 billion yuan in 2021, a year-on-year decrease of 22.63%; The net profit attributable to the parent company lost 100 million yuan, a year-on-year decrease of 226 million yuan. The continuous performance loss in 2021 is mainly caused by the national centralized purchase policy, the increase of the company’s R & D investment, non operating expenses and other comprehensive factors. In 2021, the company’s R & D investment reached 118 million yuan, a year-on-year increase of 59.74%, accounting for 9.63% of the annual operating revenue. The company is vigorously distributing strategic related fields such as anti-tumor, digestive tract and ophthalmology.
© China Stock Market News